Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Zöhrer, E; Alisi, A; Jahnel, J; Mosca, A; Della Corte, C; Crudele, A; Fauler, G; Nobili, V.
Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial.
Appl Physiol Nutr Metab. 2017; 42(9):948-954
Doi: 10.1139/apnm-2016-0689
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Zöhrer Evelyn
- Co-authors Med Uni Graz
- Fauler Günter
- Jahnel Jörg
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Nonalcoholic steatohepatitis (NASH), a progressive form of nonalcoholic fatty liver disease, is one of the most common hepatic diseases in children. We conducted a randomized controlled clinical trial on children with biopsy-proven NASH based on a combinatorial nutritional approach compared with placebo. Participants were assigned to lifestyle modification plus placebo or lifestyle modification plus a mix containing docosahexaenoic acid, choline, and vitamin E (DHA-CHO-VE). Forty children and adolescents participated in the entire trial. The primary outcome was the improvement of liver hyperechogenicity. Secondary outcomes included alterations of alanine aminotransferase (ALT) and other metabolic parameters. Furthermore, changes of serum bile acids (BA) and plasma fibroblast growth factor 19 (FGF19) levels were evaluated as inverse biomarkers of disease severity. At the end of the study, we observed a significant decrease in severe steatosis in the treatment group (50% to 5%, p = 0.001). Furthermore, although the anthropometric and biochemical measurements in the placebo and DHA-CHO-VE groups were comparable at baseline, at the end of the study ALT and fasting glucose levels improved only in the treatment group. Finally, we found that BA levels were not influenced whereas FGF19 levels were significantly increased by DHA-CHO-VE. The results suggest that a combination of DHA, VE, and CHO could improve steatosis and reduce ALT and glucose levels in children with NASH. However, further studies are needed to assess the impact of a DHA and VE combination on repair of liver damage in paediatric NASH.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Biomarkers - blood
- Biopsy -
- Child -
- Child Nutritional Physiological Phenomena -
- Choline - adverse effects
- Choline - therapeutic use
- Combined Modality Therapy - adverse effects
- Dietary Supplements - adverse effects
- Disease Progression -
- Docosahexaenoic Acids - adverse effects
- Docosahexaenoic Acids - therapeutic use
- Double-Blind Method -
- Exercise -
- Female -
- Follow-Up Studies -
- Healthy Lifestyle -
- Humans -
- Liver - pathology
- Liver - physiopathology
- Male -
- Non-alcoholic Fatty Liver Disease - blood
- Non-alcoholic Fatty Liver Disease - diet therapy
- Non-alcoholic Fatty Liver Disease - pathology
- Non-alcoholic Fatty Liver Disease - physiopathology
- Severity of Illness Index -
- Vitamin E - adverse effects
- Vitamin E - therapeutic use
- Find related publications in this database (Keywords)
- bile acids
- choline
- docosahexaenoic acid
- FGF19
- nonalcoholic fatty liver disease
- steatosis
- vitamin E